Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history

Respirology

Volumn 21, Issue 3, 2016, Pages 427-437

  Sgalla, Giacomo ^a   Biffi, Alice ^a,b   Richeldi, Luca ^a  

^a University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Diagnosis; Epidemiology; Idiopathic pulmonary fibrosis; Interstitial lung disease; Natural history

Indexed keywords

CLINICAL FEATURE; DISEASE EXACERBATION; EARLY DIAGNOSIS; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTORY; HUMAN; INCIDENCE; LUNG BIOPSY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL; TRANSBRONCHIAL LUNG CRYOBIOPSY; DIAGNOSTIC IMAGING; EXTRACELLULAR MATRIX; HEALTH; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM;

DIAGNOSTIC IMAGING; EXTRACELLULAR MATRIX; GLOBAL HEALTH; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; PREVALENCE;

EID: 84947983072     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12683     Document Type: Review

References (89)

1. King TE, Pardo A, Selman M,. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
2. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733-748.
3. Navaratnam VFK, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB,. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011; 66: 462-467.
4. Vancheri C, Failla M, Crimi N, Raghu G,. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 2010; 35: 496-504.
5. Collard HR, Chen S-Y, Yeh W-S, Li Q, Lee Y-C, Wang A, Raghu G,. Health care utilization and costs in idiopathic pulmonary fibrosis in United States medicare beneficiaries aged 65 years and older. Ann. Am. Thorac. Soc. 2015; 12: 981-987.
6. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
7. Cottin V, Cordier JF,. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur. Respir. J. 2012; 40: 519-521.
8. King TE Jr, Pardo A, Selman M,. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
9. Vij R, Noth I, Strek ME,. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140: 1292-1299.
10. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur. Respir. J. 2015; 46: 976-987.
11. American Thoracic Society (ATS) at ERSE. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am. J. Respir. Crit. Care Med. 2000; 161: 646-664.
12. Sundaram B, Gross BH, Martinez FJ, Oh E, Müller NL, Schipper M, Kazerooni EA,. Accuracy of high-resolution ct in the diagnosis of diffuse lung disease: effect of predominance and distribution of findings. Am. J. Roentgenol. 2008; 191: 1032-1039.
13. du Bois RM,. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2012; 21: 141-146.
14. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur. Respir. J. 2013; 42: 750-757.
15. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071-2082.
16. Arakawa H, Honma K,. Honeycomb lung: history and current concepts. Am. J. Roentgenol. 2011; 196: 773-782.
17. Watadani T, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K, Bankier AA, Lee KS, Muller NL, Song JW, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013; 266: 936-944.
18. Sumikawa H, Johkoh T, Colby TV, Ichikado K, Suga M, Taniguchi H, Kondoh Y, Ogura T, Arakawa H, Fujimoto K, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am. J. Respir. Crit. Care Med. 2008; 177: 433-439.
19. Walsh SL, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM,. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014; 69: 216-222.
20. Walsh SF, Sverzellati N, Devaraj A, Wells A, Hansell D,. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur. Radiol. 2012; 22: 1672-1679.
21. Fell CD, Martinez FJ, Liu LX, Murray S, Han MK, Kazerooni EA, Gross BH, Myers J, Travis WD, Colby TV, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2010; 181: 832-837.
22. Raghu G, Lynch D, Godwin JD, Webb R, Colby TV, Leslie KO, Behr J, Brown KK, Egan JJ, Flaherty KR, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir. Med. 2014; 2: 277-284.
23. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. NEJM 2011; 365: 1079-1087.
24. Raghu G, Wells A, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM,. Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS trials in IPF. Am. J. Respir. Crit. Care Med. 2015; 191: A1022.
25. Park JH, Kim DK, Kim DS, Koh Y, Lee SD, Kim WS, Kim WD, Park SI,. Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. Eur. J. Cardiothorac Surg. 2007; 31: 1115-1119.
26. Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, Carretta E, Tantalocco P, Piciucchi S, Ravaglia C, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS ONE 2014; 9: e86716.
27. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM,. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164: 1171-1181.
28. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ,. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am. J. Respir. Crit. Care Med. 2011; 184: 842-847.
29. Putman RK, Rosas IO, Hunninghake GM,. Genetics and early detection in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2014; 189: 770-778.
30. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 2011; 364: 1503-1512.
31. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, Nishino M, Araki T, Zazueta OE, Kurugol S, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N. Engl. J. Med. 2013; 368: 2192-2200.
32. Jin GY, Lynch D, Chawla A, Garg K, Tammemagi MC, Sahin H, Misumi S, Kwon KS,. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 2013; 268: 563-571.
33. Cordier JF, Cottin V,. Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur. Respir. J. 2013; 42: 916-923.
34. Thomeer M, Demedts M, Vandeurzen K,. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin. Belg. 2001; 56: 163-172.
35. Tinelli C, De Silvestri A, Richeldi L, Oggionni T,. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc. Diffuse Lung Dis. 2005; 22: S4-8.
36. Raghu G, Chen S-Y, Yeh W-S, Maroni B, Li Q, Lee Y-C, Collard HR,. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence and survival, 2001-11. Lancet Respir. Med. 2014; 2: 566-572.
37. Gribbin J, Hubbard R, Le Jeune I, Smith CJ, West J, Tata LJ,. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985.
38. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB,. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462-467.
39. Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, Bando M, Sugiyama Y, Takahashi H,. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am. J. Respir. Crit. Care Med. 2014; 190: 773-779.
40. Coultas DB, Zumwalt RE, Black WC, Sobonya RE,. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150: 967-972.
41. Mannino DM, Etzel R, Parrish RG,. Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data. Am. J. Respir. Crit. Care Med. 1996; 153: 1548-1552.
42. Johnston I, Britton J, Kinnear W, Logan R,. Rising mortality from cryptogenic fibrosing alveolitis. BMJ 1990; 301: 1017-1021.
43. Olson AL, Swigris J, Lezotte DC, Norris JM, Wilson CG, Brown KK,. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am. J. Respir. Crit. Care Med. 2007; 176: 277-284.
44. Fernandez Perez ER, Daniels C, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH,. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis a population-based study. Chest 2010; 137: 129-137.
45. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM,. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140: 221-229.
46. Ley B, Collard HR, King TE Jr,. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 431-440.
47. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Perez-Padilla R, Navarro C, Richards T, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2007; 2: e482.
48. Cottin V,. The impact of emphysema in pulmonary fibrosis. Eur. Respir. Rev. 2013; 22: 153-157.
49. Corte TJ, Wort SJ, Wells AU,. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc. Diffuse Lung Dis. 2009; 26: 7-19.
50. Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, Buccioli M, Piciucchi S, Sverzellati N, Dubini A, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015; 147: 157-164.
51. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G,. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir. Med. 2013; 1: 369-376.
52. Song JW, Hong SB, Lim CM, Koh Y, Kim DS,. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J. 2011; 37: 356-363.
53. Huie TJ, Olson AL, Cosgrove GP, Janssen WJ, Lara AR, Lynch DA, Groshong SD, Moss M, Schwarz MI, Brown KK, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology 2010; 15: 909-917.
54. Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T, Harada T, Ishimatsu Y, Matsumoto N, Naito K, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir. Res. 2014; 15: 109.
55. Idiopathic Pulmonary Fibrosis Clinical Research N, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G,. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2093-2101.
56. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040-1047.
57. Judge EP, Fabre A, Adamali HI, Egan JJ,. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 40: 93-100.
58. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007; 176: 636-643.
59. Corte TJ, Wells AU,. Diffuse alveolar damage in idiopathic pulmonary fibrosis: does aetiology matter? Respirology 2010; 15: 873-875.
60. Johannson K, Collard HR,. Acute exacerbation of idiopathic pulmonary fibrosis: a proposal. Curr. Respir. Care Rep. 2013; 2: 10.
61. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, IPFnet Investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir. Res. 2013; 14: 73.
62. Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, Huh JW, Taniguchi H, Chiu C, Boushey H, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 1698-1702.
63. Johannson KA, Vittinghoff E, Lee K, Balmes JR, Ji W, Kaplan GG, Kim DS, Collard HR,. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur. Respir. J. 2014; 43: 1124-1131.
64. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE Jr, Kim DS, Collard HR,. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 39: 352-358.
65. Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, Kimura T, Nishiyama O, Kato K, du Bois RM,. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir. Med. 2006; 100: 1753-1759.
66. Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, Nicholson AG, du Bois RM, Wells AU,. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am. J. Respir. Crit. Care Med. 2008; 177: 190-194.
67. Li X, Peng S, Wei L, Li Z,. Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis. Int. J. Clin. Exp. Med. 2014; 7: 4759-4769.
68. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S,. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 36: 1067-1072.
69. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU,. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 830-836.
70. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE Jr, Ryu JH, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-411.
71. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr,. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2014; 43: 1421-1429.
72. Best AC, Meng J, Lynch AM, Bozic CM, Miller D, Grunwald GK, Lynch DA,. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008; 246: 935-940.
73. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 2005; 172: 488-493.
74. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM,. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167: 962-969.
75. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156: 684-691.
76. Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR,. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur. Respir. J. 2015; 45: 1374-1381.
77. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE Jr, et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology 2014; 273: 570-579.
78. Maher TM,. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur. Respir. Rev. 2013; 22: 148-152.
79. Ley B, Brown KK, Collard HR,. Molecular biomarkers in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 307: L681-691.
80. Vij R, Noth I,. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl. Res. 2012; 159: 218-227.
81. Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell A-M, Braybrooke R, Molyneaux PL, McKeever TM, Wells AU, Flynn A, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir. Med. 2015; 3: 462-472.
82. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 588-594.
83. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA,. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS ONE 2009; 4: e5134.
84. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232-2239.
85. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, Broderick SM, Wade MS, Hysi P, Scuirba J, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir. Med. 2013; 1: 309-317.
86. Saini G, Porte J, Weinreb PH, Violette SM, Wallace WA, McKeever TM, Jenkins G,. alphavbeta6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur. Respir. J. 2015; 46: 486-494.
87. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES, Flaherty KR, Huffnagle GB, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir. Med. 2014; 2: 548-556.
88. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz DA, Wells AU, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2014; 190: 906-913.
89. Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, Twentyman OP, Davison AG, Curtin JJ, Crawford MB, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013; 68: 155-162.